Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

about

Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

Item

http://www.wikidata.org/entity/Q50094533

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Abaloparatide Comparator Trial ...... entarium against osteoporosis.

@en

Abaloparatide Comparator Trial In Vertebral Endpoints

@nl

type

Item

label

Abaloparatide Comparator Trial ...... entarium against osteoporosis.

@en

Abaloparatide Comparator Trial In Vertebral Endpoints

@nl

prefLabel

Abaloparatide Comparator Trial ...... entarium against osteoporosis.

@en

Abaloparatide Comparator Trial In Vertebral Endpoints

@nl

P1476

Abaloparatide Comparator Trial ...... entarium against osteoporosis.

@en

P2093

Nasser Mohammad Al Daghri

http://www.w3.org/2001/XMLSchema#string

Olivier Bruyere

http://www.w3.org/2001/XMLSchema#string

P2860

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.

Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.

P304

1811-1813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1395021

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Reginster

P577

2017-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29048260

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis